Expert Opinion on Investigational Drugs, Volume 20, Issue 10 (2011)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 20, Issue 10 (2011)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Volume 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Editorial

Article
Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors
Ahmed I El-Sakka
Pages: 1305-1309
Published online: 16 Aug 2011
AbstractforAlleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors | Full Text | References | PDF (172.4 KB)
  • 163 Views
  • 11 CrossRef citations
  • 0Altmetric

Discontinued Drug Perspective

Article
Discontinued drugs in 2010: cardiovascular drugs
Hong-ping Zhao, Xu-song Zhang & Bing-ren Xiang
Pages: 1311-1325
Published online: 26 Aug 2011
AbstractforDiscontinued drugs in 2010: cardiovascular drugs | Full Text | References | PDF (725.3 KB)
  • 417 Views
  • 6 CrossRef citations
  • 0Altmetric

Original Research

Article
The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs
Brigitte M Richard PhD, Laura R Ott, Dean Haan, Abram N Brubaker, Phaedra I Cole, Keith G Nelson, Paul E Ross, Marlon C Rebelatto & Paul E Newton
Pages: 1327-1341
Published online: 26 Aug 2011
AbstractforThe safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs | Full Text | References | PDF (859.7 KB)
  • 632 Views
  • 40 CrossRef citations
  • 0Altmetric

Reviews

Article
Thymidylate synthase inhibitors for non-small cell lung cancer
Elena Galvani, Godefridus J Peters & Elisa Giovannetti MD PhD
Pages: 1343-1356
Published online: 09 Sep 2011
AbstractforThymidylate synthase inhibitors for non-small cell lung cancer | Full Text | References | PDF (515 KB)
  • 517 Views
  • 25 CrossRef citations
  • 0Altmetric
Article
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
Pamela Jo Harris MD & Keith C Bible
Pages: 1357-1375
Published online: 13 Sep 2011
AbstractforEmerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches | Full Text | References | PDF (374.1 KB)
  • 387 Views
  • 29 CrossRef citations
  • 0Altmetric
Article
The clinical development of FLT3 inhibitors in acute myeloid leukemia
Steven Knapper DM BMBCh FRCPath MRCP
Pages: 1377-1395
Published online: 06 Sep 2011
AbstractforThe clinical development of FLT3 inhibitors in acute myeloid leukemia | Full Text | References | PDF (433.7 KB)
  • 810 Views
  • 48 CrossRef citations
  • 0Altmetric
Article
Targeting Mcl-1 for the therapy of cancer
Bridget A Quinn, Rupesh Dash, Belal Azab, Siddik Sarkar, Swadesh K Das, Sachin Kumar, Regina A Oyesanya, Santanu Dasgupta, Paul Dent, Steven Grant, Mohamed Rahmani, David T Curiel, Igor Dmitriev, Michael Hedvat, Jun Wei, Bainan Wu, John L Stebbins, John C Reed, Maurizio Pellecchia, Devanand Sarkar & Paul B Fisher
Pages: 1397-1411
Published online: 19 Aug 2011
AbstractforTargeting Mcl-1 for the therapy of cancer | Full Text | References | PDF (535.7 KB)
  • 1304 Views
  • 155 CrossRef citations
  • 0Altmetric
Article
Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?
David Bruce & Peng H Tan
Pages: 1413-1434
Published online: 25 Aug 2011
AbstractforBlocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? | Full Text | References | PDF (419.8 KB) | Supplemental
  • 260 Views
  • 10 CrossRef citations
  • 0Altmetric

Drug Evaluations

Article
Taribavirin in the treatment of hepatitis C
Paulina Deming & Sanjeev Arora
Pages: 1435-1443
Published online: 20 Aug 2011
AbstractforTaribavirin in the treatment of hepatitis C | Full Text | References | PDF (321.5 KB)
  • 171 Views
  • 5 CrossRef citations
  • 0Altmetric
Article
Vorapaxar: a novel protease-activated receptor-1 inhibitor
Paul A Gurbel MD, Young-Hoon Jeong MD PhD & Udaya S Tantry PhD
Pages: 1445-1453
Published online: 06 Aug 2011
AbstractforVorapaxar: a novel protease-activated receptor-1 inhibitor | Full Text | References | PDF (252.8 KB)
  • 682 Views
  • 16 CrossRef citations
  • 0Altmetric
Article
Entinostat for treatment of solid tumors and hematologic malignancies
Jeffrey Knipstein MD & Lia Gore MD
Pages: 1455-1467
Published online: 02 Sep 2011
AbstractforEntinostat for treatment of solid tumors and hematologic malignancies | Full Text | References | PDF (313.6 KB)
  • 870 Views
  • 87 CrossRef citations
  • 0Altmetric

Appendix

Correction
Erratum
Page: 1469
Published online: 29 Aug 2011
CitationforErratum | Full Text | PDF (25.8 KB)
  • 39 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs
Lorenza Magagnoli et al.
Review Article | Published online: 19 Jun 2024
Interleukin antagonists for atopic dermatitis: a new era of therapy
Aikaterini Tsiogka et al.
Review Article | Published online: 18 Jun 2024
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development
Luca Iorio et al.
Report | Published online: 16 Jun 2024
VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol
Amanda J. Hooper et al.
Editorial | Published online: 15 Jun 2024
Free Access
View all latest articles